Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer
|ClinicalTrials.gov Identifier: NCT00194337|
Recruitment Status : Unknown
Verified January 2007 by Abramson Cancer Center of the University of Pennsylvania.
Recruitment status was: Active, not recruiting
First Posted : September 19, 2005
Last Update Posted : January 25, 2017
RATIONALE: Diagnostic procedures, such as digital mammography, ultrasound, MRI, and PET scans, may help find breast cancer and find out how far the disease has spread.
PURPOSE: This phase II/III trial is studying digital mammography, ultrasound, MRI, and PET scans to compare how well they find the extent and spread of breast cancer in women with newly diagnosed breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Procedure: breast imaging study Procedure: comparison of screening methods Procedure: magnetic resonance imaging Procedure: positron emission tomography Procedure: radiomammography Procedure: ultrasound imaging Radiation: fludeoxyglucose F 18||Phase 2 Phase 3|
- Compare the ability of digital mammography, ultrasound, MRI, and fludeoxyglucose F 18 positron emission tomography (FDG-PET) in depicting the extent of the index lesion within an affected breast in women with newly diagnosed breast cancer.
- Compare the ability of digital mammography, ultrasound, MRI, and FDG-PET in identifying additional foci of cancer in the affected breast.
- Estimate the accuracy of FDG-PET in predicting the status of the axillary lymph nodes, using sentinel node sampling as the gold standard.
- Determine whether diffuse or multifocal cancers detected on MRI, ultrasound, digital mammography, and FDG-PET can be predicted based on mammographic, clinical, or pathologic findings.
- Based on correlation of various imaging techniques and clinical and pathological findings, generate a profile of patients at risk for mammographically and clinically occult, diffuse or multifocal disease.
- Collect pilot data on the accuracy of digital tomosynthesis in determining the extent of breast cancer (in women consenting to the contrast-enhanced tomosynthesis study).
OUTLINE: This is a prospective study. Patients are stratified according to breast density (fatty vs scattered/less than 50% dense vs heterogeneously dense/greater than 50% dense vs extremely dense), presentation (palpable abnormalities vs imaging abnormalities only), and image findings (density vs calcification).
Patients undergo MRI, ultrasound, digital mammography, and fludeoxyglucose F 18 positron emission tomography. Results of imaging are compared by a panel of physicians to determine efficacy of each method. Consenting patients also undergo digital tomosynthesis with or without contrast enhancement.
PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Multimodality Breast Imaging: Project 3-Lesion Staging|
|Study Start Date :||October 1999|
|Actual Primary Completion Date :||July 2012|
- Size of the index lesion (3 dimensions and tumor volume)
- Relative sensitivity/specificity of imaging in identifying additional cancer foci at least 2 cm from the index lesion margin
- Relative yield of imaging in detecting lymph node and distant metastases
- Positive predictive value of imaging-identified suspicious incidental lesions
- Negative predictive value of imaging (compared to mastectomy sectioning) for identifying unifocal disease
- Imaging features predictive of lymph node status
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00194337
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Abass Alavi, MD||Abramson Cancer Center of the University of Pennsylvania|